Insight Molecular Diagnostics Q2 FY26 net loss widens to $11.26 million; revenue falls to $239,000
IMDX•Q2 FY26 financial results
Insight Molecular Diagnostics posted second-quarter 2026 revenue of $239,000, down 53.86% from $518,000 a year earlier.
Net loss widened to $11.3 million, or $0.31 per share, from $9.74 million, or $0.30 per share.
Non-GAAP adjusted net loss widened to $8.32 million, or $0.23 per share, from $6.43 million, or $0.20 per share.
FDA review of GraftAssureDx
The FDA completed the current phase of substantive review of GraftAssureDx in late July and requested additional information as the review advances toward expected marketing authorization.
Cash position and operating cash use
Cash, cash equivalents, and restricted cash totaled $18.7 million at quarter-end. Operating cash outflow was $9.27 million.
